Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1989-06-29
1990-12-25
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Lymphokine
514 2, 514 8, 514 21, 514886, 530351, A61K 3700
Patent
active
049801600
ABSTRACT:
This invention relates to combinations and methods for the treatment of malignant and non-malignant diseases. More particularly, this invention relates to combinations of natural or recombinant tumor necrosis factors ("TNF") and non-steroidal anti-inflammatory agents, such as indomethacin and ibuprofen, useful for the growth inhibition or killing of transformed cells. According to this invention, the non-steroidal anti-inflammatory agents are used to reduce or eliminate the toxic side effects of high doses of TNFs employed in the treatment of malignant and non-malignant neoplastic diseases. Advantageously, the combinations and methods of this invention allow the administration of higher doses of TNF than those tolerated in conventional treatment regimens based upon TNF alone.
REFERENCES:
patent: 4500540 (1985-02-01), Hamilton et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4791101 (1988-12-01), Adolf
patent: 4822605 (1989-04-01), Powell
patent: 4857314 (1989-08-01), O'Connor et al.
patent: 4863727 (1989-09-01), Zimmerman
patent: 4879111 (1989-11-01), Chang
patent: 4894225 (1989-01-01), Zimmerman
Ghiara, Immunol 139, 1987, pp. 3676-3679.
Alexander et al., CA vol. 107, 1987, #327449.
Watanabe et al., CA vol. 108, 1988 #87353n.
Conti et al., Int. J. Immunopharmae vol. 10 1988, pp. 907-911.
Kull et al., Concer Res. vol. 41, 1981, pp. 4885-4890.
Baldwell et al., Cancer Res. vol. 46, 1986, pp. 3990-3993.
Beutler et al., Science 229, 1985, pp. 869-871.
Beutler et al. Nature 320, 1986, pp. 584-588.
Kawakawi et al., Biochem. Brophys. Res. Comm. 141 (2) 1986, pp. 482-487.
Bachwich et al., Biochem. Biophys. Res. Comm., 136(1) 1986, pp. 94-101.
Kunhel et al., Biochem. Biophys. Res. Comm, 137(1) 1986, pp. 404-410.
P. M. Almqvist et al. "Treatment of Experimental Canine Endotoxin Shock with Ibuprofen, a Cyclooygenase Inhibitor," Circulatory Shock, 13, pp. 227-232 (1984).
F. R. Balkwill et al., "Human Tumor Xenografts Treated with Recombinant Human Tumor Necrosis Factor Alone or in Combination with Interferons," Cancer Research, 46, pp. 3990-3993 (1986).
H. Bult et al., "Blood Levels of 6-Keto-PGF.sub.1.alpha., the Stable Metabolite of Prostacyclin during Endotoxin-Induced Hypotension," Arch. Int. Pharmacodyn., 236, pp. 285-286 (1978).
E. A. Carswell et al., "An Endotoxin-Induced Serum Factor that causes Necrosis of Tumors," Proc. Nat. Acad. Sci. U.S.A., 72, pp. 3666-3670 (1975).
J. A. Cook et al., "Elevated Thromboxane Levels in the Rat during Endotoxic Shock; Protective Effects of Imidazole, 13-Azaprostanoic Acid, or Essential Fatty Acid Deficiency," J. Clin. Invest., 65, pp. 227-230 (1980).
J. M. Dayer et al., "Cachetin/Tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E.sub.2 Production by Human Synovial Cells and Dermal Fibroblasts," J. Exp. Med., 162, pp. 2163-2168 (1985).
J. R. Fletcher in Biological Protection with Prostaglandins, I, pp. 65-72 (1985).
P. V. Halushka et al., "Protective Effects of Aspirin in Endotoxic Shock," J. Pharm. and Exper. Thera., 218, pp. 464-469 (1981).
K. Haranaka et al., "Antitumor Activity of Murine Tumor Necrosis Factor (TNF) against Transplanted Murine Tumors and Heterotransplanted Human Tumors in Nude Mice," Int. J. Cancer, 34, pp. 263-267 (1984).
T. Kudo et al., "Antitumor Activity of Indomethacin on on Methylazoxymethanol-induced Large Bowel Tumors in Rats," Gann, 71, pp. 260-264 (1980).
L. J. Old, "Tumor Necrosis Factor (TNF)," Science, 230, pp. 630-632 (1985).
N. O. Olsson et al., "Effect of Indomethacin on the Growth of Colon Cancer Cells in Syngeneic Rats," Int. J. Immunopharmac., 6, pp. 329-334 (1984).
J. R. Parratt and R. M. Sturgess, "E. Coli Endotoxin Shock in the Cat; Treatment with Indomethacin," Br. J. Pharmac., 53, pp. 485-488 (1975).
M. Pollard and P. H. Luckert, "Prolonged Antitumor Effect of Indomethacin on Autochthonous Intestinal Tumors in Rats," JNCI, 70, pp. 1103-1105 (1983).
T. Shirai et al., "Cloning and Expression in Escherichia coli of the Gene for Human Tumor Necrosis Factor," Nature, 313, pp. 803-806 (1985).
B. L. Short et al., "Indomethacin Improves Survival in Gram-Negative Sepsis," Advances in Shock Research, 6, pp. 27-36 (1981).
"Tumor Necrosis Factor Less Toxic in Trials," Medical World News (Oct. 13, 1986).
J. Wan and R. F. Grimble, "Inhibitory Effects of Indomethacin on some features of the Metabolic response to Escherichia coli Endotoxin in Rats," Proc. Nutritional Soc., 45, p. 51A (1986).
A. M. Wang et al., "Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor," Science, 228, pp. 149-154 (1985).
B. D. Williamson et al., "Human Tumor Necrosis Factor produced by Human B-Cell Lines: Synergistic Cytotoxic Interaction with Human Interferon," Proc. Natl. Acad. Sci. U.S.A., 80, pp. 5397-5401 (1983).
W. C. Wise et al., "Implications for Thromboxane A.sub.2 in the Pathogenesis of Endotoxic Shock," Advances in Shock Research, 6, pp. 83-91 (1981).
Fiers Walter C.
Goldberg Alfred L.
Kettelhut Isis C.
Biogen Inc.
Draper Garnette D.
Haley, Jr. James F.
Massaro Jane A.
President and Fellows of Harvard College
LandOfFree
Combinations of tumor necrosis factors and anti-inflammatory age does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of tumor necrosis factors and anti-inflammatory age, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of tumor necrosis factors and anti-inflammatory age will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1161577